| 1 |
35512188 | Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. | 2022 May 5 |
5 |
| 2 |
32251398 | Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome. | 2020 May |
1 |
| 3 |
32323826 | Antitumor effect of lenalidomide in malignant glioma cell lines. | 2020 May |
1 |
| 4 |
30598450 | Dual inhibition of MDM2 and MDM4 in virus-positive Merkel cell carcinoma enhances the p53 response. | 2019 Jan 15 |
1 |
| 5 |
30608891 | Lenalidomide for the treatment of mantle cell lymphoma. | 2019 Apr |
1 |
| 6 |
29269520 | Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide. | 2018 Apr |
1 |
| 7 |
30097406 | SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q. | 2018 Oct |
1 |
| 8 |
27884971 | Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations. | 2017 Mar |
1 |
| 9 |
27967292 | The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications. | 2017 Aug |
1 |
| 10 |
29296763 | A case of lenalidomide-dependent myelodysplastic syndrome. | 2017 Jul 11 |
1 |
| 11 |
26967821 | Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. | 2016 Mar 11 |
1 |
| 12 |
27133825 | Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS). | 2016 Sep |
1 |
| 13 |
26075044 | Recent Advances in the 5q- Syndrome. | 2015 |
1 |
| 14 |
24627193 | Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide. | 2014 May |
1 |
| 15 |
24682512 | p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). | 2014 Jun |
1 |
| 16 |
24990888 | Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53. | 2014 Sep 4 |
2 |
| 17 |
25295231 | PP2A: The Achilles Heal in MDS with 5q Deletion. | 2014 |
1 |
| 18 |
22525275 | Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. | 2013 Feb 28 |
3 |
| 19 |
23614682 | Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. | 2013 Jul |
2 |
| 20 |
24043769 | TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. | 2013 Oct 1 |
2 |
| 21 |
21968939 | Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo. | 2012 Jun 1 |
1 |
| 22 |
22109882 | The immunomodulatory drug lenalidomide restores a vitamin D sensitive phenotype to the vitamin D resistant breast cancer cell line MDA-MB-231 through inhibition of BCL-2: potential for breast cancer therapeutics. | 2012 Feb |
1 |
| 23 |
22261445 | p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide. | 2012 Feb |
4 |
| 24 |
22933333 | Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion. | 2012 Dec |
1 |
| 25 |
23556117 | Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion. | 2012 Apr |
1 |
| 26 |
21321360 | Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. | 2011 Apr 28 |
1 |
| 27 |
19797731 | Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. | 2009 Dec |
1 |